Diamyd Medical AB (FRA:DMN) Cyclically Adjusted FCF per Share: €-0.09 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
41 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Cyclically Adjusted FCF per Share?

Diamyd Medical AB FRA:DMN -3.97% 41 Cyclically Adjusted FCF per Share is €-0.09 as of May. 2026. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Diamyd Medical AB's adjusted free cash flow per share for the three months ended in May. 2026 was €-0.044. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.09 for the trailing ten years ended in May. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Diamyd Medical AB was 23.90% per year. The lowest was 7.10% per year. And the median was 21.60% per year.

As of today (2026-08-10), Diamyd Medical AB's current stock price is €0.0725. Diamyd Medical AB's Cyclically Adjusted FCF per Share for the quarter that ended in May. 2026 was €-0.09. Diamyd Medical AB's Cyclically Adjusted Price-to-FCF of today is .


Diamyd Medical AB  (FRA:DMN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Diamyd Medical AB Cyclically Adjusted FCF per Share Related Terms


Diamyd Medical AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Cyclically Adjusted FCF per Share Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.15 -0.09 -0.09 -0.11

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.11 -0.11 -0.12 -0.09

FRA:DMN vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:DMN
41GF Score
Diamyd Medical AB FRA:DMN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Diamyd Medical AB's adjusted Free Cash Flow per Share data for the three months ended in May. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=-0.044/134.1100*134.1100
=-0.044

Current CPI (May. 2026) = 134.1100.

Diamyd Medical AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201608 -0.012 100.968 -0.016
201611 -0.016 101.517 -0.021
201702 -0.018 102.037 -0.024
201705 -0.018 102.679 -0.024
201708 -0.020 103.138 -0.026
201711 -0.021 103.413 -0.027
201802 -0.019 103.678 -0.025
201805 -0.016 104.632 -0.021
201808 -0.015 105.197 -0.019
201811 -0.018 105.443 -0.023
201902 -0.012 105.641 -0.015
201905 -0.012 106.895 -0.015
201908 -0.074 106.716 -0.093
201911 -0.008 107.345 -0.010
202002 0.049 106.742 0.062
202005 -0.009 106.882 -0.011
202008 -0.010 107.571 -0.012
202011 -0.022 107.549 -0.027
202102 -0.021 108.190 -0.026
202105 -0.037 108.838 -0.046
202108 -0.074 109.780 -0.090
202111 -0.057 111.069 -0.069
202202 -0.026 112.834 -0.031
202205 -0.043 116.746 -0.049
202208 -0.038 120.573 -0.042
202211 -0.034 123.803 -0.037
202302 -0.033 126.321 -0.035
202305 -0.030 128.034 -0.031
202308 -0.041 129.560 -0.042
202311 -0.031 130.958 -0.032
202402 -0.036 132.046 -0.037
202405 -0.033 132.818 -0.033
202408 -0.026 132.052 -0.026
202411 -0.037 133.000 -0.037
202502 -0.042 133.744 -0.042
202505 -0.042 133.064 -0.042
202508 -0.025 133.440 -0.025
202511 -0.029 133.340 -0.029
202602 -0.027 134.410 -0.027
202605 -0.044 134.110 -0.044

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.09 mean?
Diamyd Medical AB (FRA:DMN) has a Cyclically Adjusted FCF per Share of €-0.09 as of May. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's Cyclically Adjusted FCF per Share too high?
Diamyd Medical AB's current Cyclically Adjusted FCF per Share is €-0.09. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Diamyd Medical AB's Cyclically Adjusted FCF per Share of €-0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Cyclically Adjusted FCF per Share is €-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.09. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Cyclically Adjusted FCF per Share is €-0.09 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • Cyclically Adjusted FCF per Share: €-0.09
  • GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for FRA:DMN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value